Identification

Name
Dihydrocodeine
Accession Number
DB01551
Type
Small Molecule
Groups
Approved, Illicit
Description

Dihydrocodeine is an opioid analgesic used as an alternative or adjunct to codeine to treat moderate to severe pain, severe dyspnea, and cough.

It is semi-synthetic, and was developed in Germany in 1908 during an international search to find a more effective antitussive agent to help reduce the spread of airborne infectious diseases such as tuburculosis. It was marketed in 1911. [Wikipedia]

Structure
Thumb
Synonyms
  • DHC
  • Remedacen
External IDs
IDS-ND-008(SECT.2) / NSC-231319
Product Ingredients
IngredientUNIICASInChI Key
Dihydrocodeine bitartrate8LXS95BSA95965-13-9ZGSZBVAEVPSPFM-HYTSPMEMSA-N
Dihydrocodeine hydrobromideNot AvailableNot AvailableNot applicable
Dihydrocodeine hydrochloride9073288YPO36418-29-8VMZXMTVGOAQUEN-FFHNEAJVSA-N
Dihydrocodeine hydroiodide6D04Y0152T5965-15-1QXBJOHDQNJOLNA-FFHNEAJVSA-N
Dihydrocodeine methyliodideNot AvailableNot AvailableNot applicable
Dihydrocodeine phosphate5D9XI60ASE24204-13-5HFBYLYCMISIEMM-FFHNEAJVSA-N
Dihydrocodeine sulfateNot AvailableNot AvailableNot applicable
Dihydrocodeine tartrateNot AvailableNot AvailableNot applicable
International/Other Brands
Codidol / Contugesic / Dehace / DF-118 Forte / Dicogesic / Hydrocodin / Remedacen
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Acetaminophen, Caffeine and Dihydrocodeine BitartrateDihydrocodeine bitartrate (16 mg/1) + Acetaminophen (325 mg/1) + Caffeine (30 mg/1)TabletOralLarken Laboratories, Inc.2016-10-04Not applicableUs
Acetaminophen, Caffeine, Dihydrocodeine BitartrateDihydrocodeine bitartrate (16 mg/1) + Acetaminophen (320.5 mg/1) + Caffeine (30 mg/1)CapsuleOralPreferreed Pharmaceuticals Inc.2015-09-11Not applicableUs
Acetaminophen, Caffeine, Dihydrocodeine BitartrateDihydrocodeine bitartrate (16 mg/1) + Acetaminophen (320.5 mg/1) + Caffeine (30 mg/1)CapsuleOralbryant ranch prepack2015-08-052017-06-20Us
Acetaminophen, Caffeine, Dihydrocodeine BitartrateDihydrocodeine bitartrate (16 mg/1) + Acetaminophen (320.5 mg/1) + Caffeine (30 mg/1)CapsuleOralXspire Pharma2015-08-05Not applicableUs
Acetaminophen, Caffeine, Dihydrocodeine BitartrateDihydrocodeine bitartrate (16 mg/1) + Acetaminophen (320.5 mg/1) + Caffeine (30 mg/1)CapsuleOralMesource Pharmaceuticals2015-08-05Not applicableUs
Aspirin, Caffeine, and Dihydrocodeine BitartrateDihydrocodeine bitartrate (16 mg/1) + Acetylsalicylic acid (356.4 mg/1) + Caffeine (30 mg/1)CapsuleOralCaraco Pharmaceutical Laboratories, Ltd.2012-10-01Not applicableUs
Centussin DhcDihydrocodeine bitartrate (3 mg/5mL) + Brompheniramine maleate (4 mg/5mL) + Phenylephrine hydrochloride (7.5 mg/5mL)LiquidOralCenturion Labs2009-11-242016-10-13Us
Dihydrocodeine Bitartrate, Acetaminophen and CaffeineDihydrocodeine bitartrate (32 mg/1) + Acetaminophen (712.8 mg/1) + Caffeine (60 mg/1)TabletOralPhysicians Total Care, Inc.2008-05-20Not applicableUs
J-cof DhcDihydrocodeine bitartrate (7.5 mg/5mL) + Brompheniramine maleate (3 mg/5mL) + Pseudoephedrine hydrochloride (15 mg/5mL)LiquidOralJay Mac Pharmaceuticals2008-06-302016-10-13Us
J-max DhcDihydrocodeine bitartrate (7.5 mg/5mL) + Guaifenesin (100 mg/5mL)LiquidOralJay Mac Pharmaceuticals2008-06-302016-10-13Us
Categories
UNII
N9I9HDB855
CAS number
125-28-0
Weight
Average: 301.3801
Monoisotopic: 301.167793607
Chemical Formula
C18H23NO3
InChI Key
RBOXVHNMENFORY-DNJOTXNNSA-N
InChI
InChI=1S/C18H23NO3/c1-19-8-7-18-11-4-5-13(20)17(18)22-16-14(21-2)6-3-10(15(16)18)9-12(11)19/h3,6,11-13,17,20H,4-5,7-9H2,1-2H3/t11-,12+,13-,17-,18-/m0/s1
IUPAC Name
(1S,5R,13R,14S,17R)-10-methoxy-4-methyl-12-oxa-4-azapentacyclo[9.6.1.0¹,¹³.0⁵,¹⁷.0⁷,¹⁸]octadeca-7(18),8,10-trien-14-ol
SMILES
[H][[email protected]@]12OC3=C(OC)C=CC4=C3[[email protected]@]11CCN(C)[[email protected]]([H])(C4)[[email protected]]1([H])CC[[email protected]@H]2O

Pharmacology

Indication

Dihydrocodeine is used for the treatment of moderate to severe pain, including post-operative and dental pain [2]. It can also be used to treat chronic pain [1], breathlessness and coughing.

In heroin addicts, dihydrocodeine has been used as a substitute drug, in doses up to 2500mg/day to treat addiction. [http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2014322/]

Structured Indications
Pharmacodynamics

Possible opioid related side effects include, but are not limited to, drowsiness, nausea, headache, dry mouth, constipation, difficulty passing urine, and mild euphoria.

Mechanism of action

Dihydrocodeine is metabolized to dihydromorphine -- a highly active metabolite with a high affinity for mu opioid receptors. [3]

Absorption

Bioavailability is low (approximately 20%) if administered orally. This may be due to poor gastrointestinal absorption. It is also likely due to pre-systemic metabolism by the liver and intestinal wall. [2]

The AUCs after oral and intravenous administration are similar (3203ug/l/h and 3401ug/l/h, respectively). [2]

Time to peak values are 1.6 and 1.8hours for a 30mg and 60mg dose, respectively. The concentrations achieved were 71.8 ug/1 and 146 ug/1, respectively. [2]

Volume of distribution

The disposition of dihydrocodeine is described as a two compartment model. [2]

Protein binding
Not Available
Metabolism

Metabolized in the liver by CYP 2D6 into an active metabolite, dihydromorphine, and by CYP 3A4 into secondary primary metabolite, nordihydrocodeine. A third primary metabolite is dihydrocodeine-6-glucuronide. [1]

The time for mean peak concentration in acid metabolites is 1.76h and 1.98h for a 30 and 60mg dose, respectively. The concentrations achieved were 563 ug/1 and 1476 ug/1, respectively. [2]

Route of elimination

Renal elimination and urinary excretion. [1]

Half life

4h

Clearance

Plasma clearance is approximately 300ml/min. [2]

The pharmacokinetics of dihydrocodeine and active metabolite dihydromorphine have been reported to be linear. [1]

The decline in plasma dihydrocodeine concentrations after intravenous administration has been described as bi-exponential, with a sleep decline in the initial 2h following administration, followed by a mono-exponential decline thereafter. Clearance was not dose dependent. [2]

Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylamphetamine2,5-Dimethoxy-4-ethylamphetamine may increase the analgesic activities of Dihydrocodeine.Experimental, Illicit
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may increase the analgesic activities of Dihydrocodeine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamine4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Dihydrocodeine.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with 7-Nitroindazole.Experimental
7,8-Dichloro-1,2,3,4-tetrahydroisoquinolineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Experimental
AbirateroneThe serum concentration of Dihydrocodeine can be increased when it is combined with Abiraterone.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Aceprometazine.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Acetazolamide.Approved, Vet Approved
AclidiniumThe risk or severity of adverse effects can be increased when Aclidinium is combined with Dihydrocodeine.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Agomelatine.Approved, Investigational
AlaproclateDihydrocodeine may increase the serotonergic activities of Alaproclate.Experimental
AlcuroniumThe risk or severity of adverse effects can be increased when Alcuronium is combined with Dihydrocodeine.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Dihydrocodeine.Approved, Illicit
AlimemazineAlimemazine may increase the hypotensive activities of Dihydrocodeine.Approved, Vet Approved
AllopregnanoloneThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Allopregnanolone.Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Dihydrocodeine.Approved, Illicit, Investigational
AlvimopanThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Alvimopan.Approved
AmilorideThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Amiloride.Approved
AmiodaroneThe metabolism of Dihydrocodeine can be decreased when combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Amitriptyline.Approved
Ammonium chlorideAmmonium chloride may increase the excretion rate of Dihydrocodeine which could result in a lower serum level and potentially a reduction in efficacy.Approved, Vet Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Dihydrocodeine.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Amperozide.Experimental
AmphetamineAmphetamine may increase the analgesic activities of Dihydrocodeine.Approved, Illicit
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Dihydrocodeine.Approved
AprepitantThe serum concentration of Dihydrocodeine can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Dihydrocodeine.Approved, Investigational
ArtemetherThe metabolism of Dihydrocodeine can be decreased when combined with Artemether.Approved
ArticaineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Asenapine.Approved
AtazanavirThe metabolism of Dihydrocodeine can be decreased when combined with Atazanavir.Approved, Investigational
AtomoxetineThe metabolism of Dihydrocodeine can be decreased when combined with Atomoxetine.Approved
AtracuriumThe risk or severity of adverse effects can be increased when Atracurium is combined with Dihydrocodeine.Experimental, Investigational
Atracurium besylateThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Dihydrocodeine.Approved
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Dihydrocodeine.Approved, Vet Approved
AzaperoneThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Azaperone.Investigational, Vet Approved
AzelastineDihydrocodeine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzosemideThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Azosemide.Investigational
BaclofenThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Baclofen.Approved
BarbitalThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Barbital.Illicit
BenactyzineThe risk or severity of adverse effects can be increased when Benactyzine is combined with Dihydrocodeine.Withdrawn
BendroflumethiazideThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Bendroflumethiazide.Approved
BenmoxinThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Benmoxin.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Benperidol.Investigational
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Dihydrocodeine.Approved
BenzocaineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Benzocaine.Approved
BenzphetamineBenzphetamine may increase the analgesic activities of Dihydrocodeine.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Benzyl alcohol.Approved
BetaxololThe metabolism of Dihydrocodeine can be decreased when combined with Betaxolol.Approved
BiperidenThe risk or severity of adverse effects can be increased when Biperiden is combined with Dihydrocodeine.Approved, Investigational
BL-1020BL-1020 may increase the hypotensive activities of Dihydrocodeine.Investigational
BoceprevirThe metabolism of Dihydrocodeine can be decreased when combined with Boceprevir.Approved, Withdrawn
BornaprineThe risk or severity of adverse effects can be increased when Bornaprine is combined with Dihydrocodeine.Experimental
BortezomibThe metabolism of Dihydrocodeine can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Dihydrocodeine can be decreased when it is combined with Bosentan.Approved, Investigational
BrexpiprazoleThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Brexpiprazole.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Dihydrocodeine.Approved
BrofaromineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Brofaromine.Experimental
BromazepamThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Bromazepam.Approved, Illicit
BromisovalThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Bromisoval.Experimental
BromperidolThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Bromperidol.Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Brotizolam.Approved, Investigational, Withdrawn
BumetanideThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Bumetanide.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Bupivacaine.Approved, Investigational
BuprenorphineDihydrocodeine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Dihydrocodeine can be decreased when combined with Bupropion.Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Dihydrocodeine.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Dihydrocodeine.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Dihydrocodeine.Approved, Illicit, Vet Approved
CanertinibThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Canertinib.Investigational
Canrenoic acidThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Canrenoic acid.Approved, Withdrawn
CanrenoneThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Canrenone.Investigational
CarbamazepineThe metabolism of Dihydrocodeine can be increased when combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Carfentanil.Illicit, Investigational, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Carisoprodol.Approved
CaroxazoneThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Caroxazone.Withdrawn
CelecoxibThe metabolism of Dihydrocodeine can be decreased when combined with Celecoxib.Approved, Investigational
CeritinibThe serum concentration of Dihydrocodeine can be increased when it is combined with Ceritinib.Approved
CetirizineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Chloral hydrate.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Dihydrocodeine.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Chlormezanone.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Chloroprocaine.Approved
ChloroquineThe metabolism of Dihydrocodeine can be decreased when combined with Chloroquine.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Chlorothiazide.Approved, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Chlorphenamine.Approved
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Dihydrocodeine.Withdrawn
ChlorphentermineChlorphentermine may increase the analgesic activities of Dihydrocodeine.Illicit, Withdrawn
ChlorproethazineChlorproethazine may increase the hypotensive activities of Dihydrocodeine.Experimental
ChlorpromazineThe metabolism of Dihydrocodeine can be decreased when combined with Chlorpromazine.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Chlorprothixene.Approved, Investigational, Withdrawn
ChlorthalidoneThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Chlorthalidone.Approved
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Chlorzoxazone.Approved
CholecalciferolThe metabolism of Dihydrocodeine can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CicletanineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Cicletanine.Investigational
CimetidineThe metabolism of Dihydrocodeine can be decreased when combined with Cimetidine.Approved
CinacalcetThe metabolism of Dihydrocodeine can be decreased when combined with Cinacalcet.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Cinchocaine.Approved, Vet Approved
CitalopramThe metabolism of Dihydrocodeine can be decreased when combined with Citalopram.Approved
ClarithromycinThe metabolism of Dihydrocodeine can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Dihydrocodeine can be decreased when combined with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Clidinium.Approved
ClobazamThe metabolism of Dihydrocodeine can be decreased when combined with Clobazam.Approved, Illicit
ClofenamideThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Clofenamide.Experimental
clomethiazoleThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with clomethiazole.Investigational
ClomipramineThe metabolism of Dihydrocodeine can be decreased when combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Clonidine.Approved
ClopamideThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Clopamide.Experimental
ClopenthixolThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Clopenthixol.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Dihydrocodeine.Approved, Illicit
ClorexoloneThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Clorexolone.Experimental
ClothiapineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Clothiapine.Experimental
ClotrimazoleThe metabolism of Dihydrocodeine can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe metabolism of Dihydrocodeine can be decreased when combined with Clozapine.Approved
CobicistatThe serum concentration of Dihydrocodeine can be increased when it is combined with Cobicistat.Approved
CocaineThe metabolism of Dihydrocodeine can be decreased when combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Dihydrocodeine.Approved, Illicit
ConivaptanThe serum concentration of Dihydrocodeine can be increased when it is combined with Conivaptan.Approved, Investigational
CrizotinibThe metabolism of Dihydrocodeine can be decreased when combined with Crizotinib.Approved
CyclizineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Dihydrocodeine.Approved
CyclopenthiazideThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Cyclopenthiazide.Experimental
CyclopentolateThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Dihydrocodeine.Approved
CyclosporineThe metabolism of Dihydrocodeine can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyclothiazideThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Cyclothiazide.Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Cyproheptadine.Approved
DabrafenibThe serum concentration of Dihydrocodeine can be decreased when it is combined with Dabrafenib.Approved
DantroleneThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Dantrolene.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Dapiprazole.Approved
DapoxetineDihydrocodeine may increase the serotonergic activities of Dapoxetine.Investigational
DarifenacinThe metabolism of Dihydrocodeine can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Dihydrocodeine can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Dihydrocodeine can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Dihydrocodeine can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Dihydrocodeine can be decreased when combined with Delavirdine.Approved
DeramciclaneThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Dihydrocodeine.Approved
DesipramineThe metabolism of Dihydrocodeine can be decreased when combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Desloratadine.Approved, Investigational
DesmopressinThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Desmopressin.Approved
DesvenlafaxineDihydrocodeine may increase the serotonergic activities of Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Detomidine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Dexbrompheniramine.Approved
DexetimideThe risk or severity of adverse effects can be increased when Dexetimide is combined with Dihydrocodeine.Withdrawn
DexmedetomidineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Dexmedetomidine.Approved, Vet Approved
DextroamphetamineDextroamphetamine may increase the analgesic activities of Dihydrocodeine.Approved, Illicit
DextromoramideThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Dezocine.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Dihydrocodeine.Approved, Illicit, Vet Approved
DicyclomineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Dihydrocodeine.Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Diethyl ether.Experimental
DiethylpropionDiethylpropion may increase the analgesic activities of Dihydrocodeine.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Difenoxin.Approved, Illicit
DihydroergotamineThe metabolism of Dihydrocodeine can be decreased when combined with Dihydroergotamine.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Dihydromorphine.Experimental, Illicit
DiltiazemThe metabolism of Dihydrocodeine can be decreased when combined with Diltiazem.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Dimenhydrinate.Approved
DiphenhydramineThe metabolism of Dihydrocodeine can be decreased when combined with Diphenhydramine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Dihydrocodeine.Approved, Illicit
DixyrazineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Dixyrazine.Experimental
DoramectinThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Doramectin.Vet Approved
DosulepinThe metabolism of Dihydrocodeine can be decreased when combined with Dosulepin.Approved
DoxepinThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Doxepin.Approved
DoxycyclineThe metabolism of Dihydrocodeine can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Dihydrocodeine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with DPDPE.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Dihydrocodeine.Approved, Illicit
DronedaroneThe metabolism of Dihydrocodeine can be decreased when combined with Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Dihydrocodeine.Approved, Vet Approved
DrospirenoneThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Drospirenone.Approved
DrotebanolThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Drotebanol.Experimental, Illicit
DuloxetineThe metabolism of Dihydrocodeine can be decreased when combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Dyclonine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Ecgonine.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Ecopipam.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Efavirenz.Approved, Investigational
EfonidipineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Efonidipine.Approved
EliglustatThe metabolism of Dihydrocodeine can be decreased when combined with Eliglustat.Approved
EltanoloneThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Eltanolone.Investigational
EluxadolineDihydrocodeine may increase the constipating activities of Eluxadoline.Approved
EmeproniumThe risk or severity of adverse effects can be increased when Emepronium is combined with Dihydrocodeine.Experimental
EnfluraneThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Enflurane.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Entacapone.Approved, Investigational
EnzalutamideThe serum concentration of Dihydrocodeine can be decreased when it is combined with Enzalutamide.Approved
EplerenoneThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Eplerenone.Approved
ErythromycinThe metabolism of Dihydrocodeine can be decreased when combined with Erythromycin.Approved, Vet Approved
EscitalopramDihydrocodeine may increase the serotonergic activities of Escitalopram.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Dihydrocodeine.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Dihydrocodeine.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Etacrynic acid.Approved
EtanautineThe risk or severity of adverse effects can be increased when Etanautine is combined with Dihydrocodeine.Experimental
EthanolDihydrocodeine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Ethchlorvynol.Approved, Illicit, Withdrawn
EthopropazineThe risk or severity of adverse effects can be increased when Ethopropazine is combined with Dihydrocodeine.Approved
EthosuximideThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Ethotoin.Approved
EthoxzolamideThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Ethoxzolamide.Withdrawn
Ethyl carbamateThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Ethyl carbamate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Ethyl chloride.Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Etifoxine.Investigational, Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Etomidate.Approved
EtoperidoneDihydrocodeine may increase the serotonergic activities of Etoperidone.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Etorphine.Illicit, Vet Approved
EtybenzatropineThe risk or severity of adverse effects can be increased when Etybenzatropine is combined with Dihydrocodeine.Experimental
EzogabineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Fencamfamine.Approved, Illicit, Withdrawn
FenquizoneThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Fenquizone.Experimental
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Dihydrocodeine.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Dihydrocodeine.Approved
FexofenadineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Fexofenadine.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Flibanserin.Approved
FluanisoneThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Fluanisone.Experimental
FluconazoleThe metabolism of Dihydrocodeine can be decreased when combined with Fluconazole.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Flunitrazepam.Approved, Illicit
FluoxetineThe metabolism of Dihydrocodeine can be decreased when combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Dihydrocodeine.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Dihydrocodeine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Dihydrocodeine.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Fluspirilene.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Fluticasone propionate.Approved
FluvoxamineThe metabolism of Dihydrocodeine can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Dihydrocodeine can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Dihydrocodeine can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Dihydrocodeine can be increased when combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Fospropofol.Approved, Illicit, Investigational
FurazolidoneThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Furazolidone.Approved, Investigational, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Furosemide.Approved, Vet Approved
Fusidic AcidThe serum concentration of Dihydrocodeine can be increased when it is combined with Fusidic Acid.Approved
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Dihydrocodeine.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Gabapentin Enacarbil.Approved
GallamineThe risk or severity of adverse effects can be increased when Gallamine is combined with Dihydrocodeine.Experimental
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Dihydrocodeine.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Dihydrocodeine.Approved, Illicit, Investigational
GepefrineGepefrine may increase the analgesic activities of Dihydrocodeine.Experimental
GepironeThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Glutethimide.Approved, Illicit
GlycopyrroniumThe risk or severity of adverse effects can be increased when Glycopyrronium is combined with Dihydrocodeine.Approved, Investigational, Vet Approved
GuanfacineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Halazepam.Approved, Illicit, Withdrawn
HaloperidolThe metabolism of Dihydrocodeine can be decreased when combined with Haloperidol.Approved
HalothaneThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Halothane.Approved, Vet Approved
HarmalineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Harmaline.Experimental
HeroinThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Heroin.Approved, Illicit, Investigational
HexamethoniumThe risk or severity of adverse effects can be increased when Hexamethonium is combined with Dihydrocodeine.Experimental
HexobarbitalThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Hexobarbital.Approved
HomatropineThe risk or severity of adverse effects can be increased when Homatropine is combined with Dihydrocodeine.Approved
HydracarbazineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Hydracarbazine.Experimental
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneDihydrocodeine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydroflumethiazideThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Hydroflumethiazide.Approved, Investigational
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Dihydrocodeine.Approved, Illicit
HydroxyamphetamineHydroxyamphetamine may increase the analgesic activities of Dihydrocodeine.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Dihydrocodeine.Approved
HyoscyamineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Dihydrocodeine.Approved
IbopamineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Ibopamine.Experimental
IdelalisibThe serum concentration of Dihydrocodeine can be increased when it is combined with Idelalisib.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Iloperidone.Approved
ImatinibThe metabolism of Dihydrocodeine can be decreased when combined with Imatinib.Approved
ImipramineThe metabolism of Dihydrocodeine can be decreased when combined with Imipramine.Approved
IndalpineDihydrocodeine may increase the serotonergic activities of Indalpine.Investigational, Withdrawn
IndapamideThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Indapamide.Approved
IndinavirThe metabolism of Dihydrocodeine can be decreased when combined with Indinavir.Approved
IndiplonThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Indiplon.Investigational
Iofetamine I-123Iofetamine I-123 may increase the analgesic activities of Dihydrocodeine.Approved
Ipratropium bromideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Dihydrocodeine.Approved
IproclozideThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Iproclozide.Withdrawn
IproniazidThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Iproniazid.Withdrawn
IsavuconazoniumThe metabolism of Dihydrocodeine can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Isocarboxazid.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Dihydrocodeine.Approved, Vet Approved
IsoniazidThe metabolism of Dihydrocodeine can be decreased when combined with Isoniazid.Approved
IsosorbideThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Isosorbide.Approved, Investigational
IsradipineThe metabolism of Dihydrocodeine can be decreased when combined with Isradipine.Approved
ItraconazoleThe metabolism of Dihydrocodeine can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Dihydrocodeine can be increased when it is combined with Ivacaftor.Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Dihydrocodeine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Ketobemidone.Approved, Investigational
KetoconazoleThe metabolism of Dihydrocodeine can be decreased when combined with Ketoconazole.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Lamotrigine.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Levobupivacaine.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Levomethadyl Acetate.Approved, Investigational
LevomilnacipranDihydrocodeine may increase the serotonergic activities of Levomilnacipran.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Dihydrocodeine.Approved
LidocaineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Lidocaine.Approved, Vet Approved
LisdexamfetamineLisdexamfetamine may increase the analgesic activities of Dihydrocodeine.Approved, Investigational
LithiumThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Lithium.Approved
LofentanilThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Lofentanil.Illicit
LopinavirThe metabolism of Dihydrocodeine can be decreased when combined with Lopinavir.Approved
LoprazolamThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Loprazolam.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Dihydrocodeine.Approved
LorcaserinThe metabolism of Dihydrocodeine can be decreased when combined with Lorcaserin.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Lormetazepam.Approved
LovastatinThe metabolism of Dihydrocodeine can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Dihydrocodeine.Approved
LuliconazoleThe serum concentration of Dihydrocodeine can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Dihydrocodeine can be increased when combined with Lumacaftor.Approved
LumefantrineThe metabolism of Dihydrocodeine can be decreased when combined with Lumefantrine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Lurasidone.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Dihydrocodeine.Approved, Vet Approved
ManidipineThe metabolism of Dihydrocodeine can be decreased when combined with Manidipine.Approved, Investigational
MannitolThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Mannitol.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Maprotiline.Approved
MazaticolThe risk or severity of adverse effects can be increased when Mazaticol is combined with Dihydrocodeine.Experimental
MebanazineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Mebanazine.Withdrawn
MebicarThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Mebicar.Experimental
MebutizideThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Mebutizide.Experimental
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Dihydrocodeine.Approved
MeclizineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Meclizine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Medetomidine.Vet Approved
MefrusideThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Mefruside.Experimental
MelatoninThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Melperone.Approved, Investigational
MephedroneMephedrone may increase the analgesic activities of Dihydrocodeine.Investigational
MephentermineMephentermine may increase the analgesic activities of Dihydrocodeine.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Dihydrocodeine.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Meptazinol.Experimental
MersalylThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Mersalyl.Approved
MesoridazineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Mesoridazine.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Metaxalone.Approved
MethadoneThe metabolism of Dihydrocodeine can be decreased when combined with Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Methadyl Acetate.Approved, Illicit
MethamphetamineMethamphetamine may increase the analgesic activities of Dihydrocodeine.Approved, Illicit
MethanthelineThe risk or severity of adverse effects can be increased when Methantheline is combined with Dihydrocodeine.Approved, Investigational
MethapyrileneThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Methaqualone.Illicit, Withdrawn
MethazolamideThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Methazolamide.Approved
MethocarbamolThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Dihydrocodeine.Approved
MethotrimeprazineDihydrocodeine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Methoxyflurane.Approved, Investigational, Vet Approved
MethoxyphenamineMethoxyphenamine may increase the analgesic activities of Dihydrocodeine.Experimental
MethsuximideThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Methsuximide.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Methyclothiazide.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Methylecgonine.Experimental
Methylene blueMethylene blue may increase the hypotensive activities of Dihydrocodeine.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Methylphenobarbital.Approved
MeticraneThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Meticrane.Experimental
MetixeneThe risk or severity of adverse effects can be increased when Metixene is combined with Dihydrocodeine.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Metolazone.Approved
MetoprololThe metabolism of Dihydrocodeine can be decreased when combined with Metoprolol.Approved, Investigational
MetyrosineDihydrocodeine may increase the sedative activities of Metyrosine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Dihydrocodeine.Approved, Illicit
Midomafetamine3,4-Methylenedioxymethamphetamine may increase the analgesic activities of Dihydrocodeine.Experimental, Illicit, Investigational
MidostaurinThe metabolism of Dihydrocodeine can be decreased when combined with Midostaurin.Approved
MifepristoneThe serum concentration of Dihydrocodeine can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranDihydrocodeine may increase the serotonergic activities of Milnacipran.Approved
MinaprineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Minaprine.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Dihydrocodeine.Approved, Investigational
MirabegronThe metabolism of Dihydrocodeine can be decreased when combined with Mirabegron.Approved
MirtazapineDihydrocodeine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitotaneThe serum concentration of Dihydrocodeine can be decreased when it is combined with Mitotane.Approved
MMDAMMDA may increase the analgesic activities of Dihydrocodeine.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Moclobemide.Approved
MolindoneThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Molindone.Approved
MoricizineMoricizine may increase the hypotensive activities of Dihydrocodeine.Approved, Investigational, Withdrawn
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Dihydrocodeine.Approved, Investigational
MuzolimineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Muzolimine.Experimental
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Dihydrocodeine.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Dihydrocodeine.Approved
NaltrexoneThe therapeutic efficacy of Dihydrocodeine can be decreased when used in combination with Naltrexone.Approved, Investigational, Vet Approved
NefazodoneThe metabolism of Dihydrocodeine can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Dihydrocodeine can be decreased when combined with Nelfinavir.Approved
NetupitantThe serum concentration of Dihydrocodeine can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Dihydrocodeine can be increased when combined with Nevirapine.Approved
NialamideThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Nialamide.Withdrawn
NicardipineThe metabolism of Dihydrocodeine can be decreased when combined with Nicardipine.Approved
NilotinibThe metabolism of Dihydrocodeine can be decreased when combined with Nilotinib.Approved, Investigational
NitrazepamThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Nitrazepam.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Nitrous oxide.Approved, Vet Approved
NorfluraneThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Norflurane.Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Nortriptyline.Approved
OctamoxinThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Octamoxin.Withdrawn
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Dihydrocodeine.Approved, Investigational
OlaparibThe metabolism of Dihydrocodeine can be decreased when combined with Olaparib.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Olopatadine.Approved
OndansetronThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Ondansetron.Approved
OpiumThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Opium.Approved, Illicit
OrphenadrineDihydrocodeine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Dihydrocodeine can be increased when it is combined with Osimertinib.Approved
OtiloniumThe risk or severity of adverse effects can be increased when Otilonium is combined with Dihydrocodeine.Experimental, Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Dihydrocodeine.Approved
OxethazaineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Oxethazaine.Approved, Investigational
OxitropiumThe risk or severity of adverse effects can be increased when Oxitropium is combined with Dihydrocodeine.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Oxybuprocaine.Approved
OxybutyninThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Dihydrocodeine.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Dihydrocodeine.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Dihydrocodeine.Approved, Investigational, Vet Approved
OxyphenoniumThe risk or severity of adverse effects can be increased when Oxyphenonium is combined with Dihydrocodeine.Approved
PalbociclibThe serum concentration of Dihydrocodeine can be increased when it is combined with Palbociclib.Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Dihydrocodeine.Approved
PancuroniumThe risk or severity of adverse effects can be increased when Pancuronium is combined with Dihydrocodeine.Approved
PanobinostatThe serum concentration of Dihydrocodeine can be increased when it is combined with Panobinostat.Approved, Investigational
ParaldehydeDihydrocodeine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
PargylineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Pargyline.Approved
ParoxetineThe metabolism of Dihydrocodeine can be decreased when combined with Paroxetine.Approved, Investigational
Peginterferon alfa-2bThe serum concentration of Dihydrocodeine can be decreased when it is combined with Peginterferon alfa-2b.Approved
PegvisomantThe therapeutic efficacy of Pegvisomant can be decreased when used in combination with Dihydrocodeine.Approved
PenfluridolThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Penfluridol.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Dihydrocodeine.Approved, Vet Approved
PentobarbitalThe metabolism of Dihydrocodeine can be increased when combined with Pentobarbital.Approved, Vet Approved
PentoliniumThe risk or severity of adverse effects can be increased when Pentolinium is combined with Dihydrocodeine.Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Dihydrocodeine.Approved
PerazineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Perazine.Investigational
PerospironeThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Dihydrocodeine.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Dihydrocodeine.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Phenazocine.Experimental
PhenelzineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Phenelzine.Approved
PhenglutarimideThe risk or severity of adverse effects can be increased when Phenglutarimide is combined with Dihydrocodeine.Experimental
PhenibutThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Phenibut.Experimental
PheniprazineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Pheniprazine.Withdrawn
PhenobarbitalThe metabolism of Dihydrocodeine can be increased when combined with Phenobarbital.Approved
PhenoperidineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Phenoperidine.Experimental
PhenoxyethanolThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Phenoxyethanol.Approved
PhenoxypropazineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Phenoxypropazine.Withdrawn
PhenterminePhentermine may increase the analgesic activities of Dihydrocodeine.Approved, Illicit
PhenytoinThe metabolism of Dihydrocodeine can be increased when combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Dihydrocodeine.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Pipamperone.Approved, Investigational
PipecuroniumThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Dihydrocodeine.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Pipotiazine.Approved, Investigational
PirenzepineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Dihydrocodeine.Approved
PiretanideThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Piretanide.Experimental
PiritramideThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Piritramide.Investigational
PirlindoleThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Pirlindole.Approved
PivhydrazineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Pivhydrazine.Withdrawn
PizotifenThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Pizotifen.Approved
PolythiazideThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Polythiazide.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Pomalidomide.Approved
PosaconazoleThe metabolism of Dihydrocodeine can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PotassiumThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Potassium.Approved
Potassium CitrateThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Potassium Citrate.Approved, Vet Approved
PramipexoleDihydrocodeine may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Prazepam.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Dihydrocodeine.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Prilocaine.Approved
PrimidoneThe metabolism of Dihydrocodeine can be increased when combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Procaine.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Dihydrocodeine.Approved, Vet Approved
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Dihydrocodeine.Approved
PromazineThe metabolism of Dihydrocodeine can be decreased when combined with Promazine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Promethazine.Approved
PropanididThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Propanidid.Experimental
PropanthelineThe risk or severity of adverse effects can be increased when Propantheline is combined with Dihydrocodeine.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Proparacaine.Approved, Vet Approved
PropiopromazinePropiopromazine may increase the hypotensive activities of Dihydrocodeine.Vet Approved
PropiverineThe risk or severity of adverse effects can be increased when Propiverine is combined with Dihydrocodeine.Approved, Investigational
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Dihydrocodeine.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Propoxycaine.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Protriptyline.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Proxibarbal.Experimental
PSD502The risk or severity of adverse effects can be increased when Dihydrocodeine is combined with PSD502.Investigational
PseudoephedrinePseudoephedrine may increase the analgesic activities of Dihydrocodeine.Approved
QuazepamThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Quazepam.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Dihydrocodeine.Approved
QuinethazoneThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Quinethazone.Approved
QuinidineQuinidine may decrease the analgesic activities of Dihydrocodeine.Approved
QuinineThe metabolism of Dihydrocodeine can be decreased when combined with Quinine.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Quinisocaine.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Ramelteon.Approved, Investigational
RamosetronDihydrocodeine may increase the constipating activities of Ramosetron.Approved, Investigational
RanolazineThe metabolism of Dihydrocodeine can be decreased when combined with Ranolazine.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Rasagiline.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Dihydrocodeine.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Remoxipride.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Dihydrocodeine.Approved, Investigational
RifabutinThe metabolism of Dihydrocodeine can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Dihydrocodeine can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Dihydrocodeine can be increased when combined with Rifapentine.Approved
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Dihydrocodeine.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Ritanserin.Investigational
RitobegronRitobegron may increase the analgesic activities of Dihydrocodeine.Investigational
RitonavirThe metabolism of Dihydrocodeine can be decreased when combined with Ritonavir.Approved, Investigational
RolapitantThe metabolism of Dihydrocodeine can be decreased when combined with Rolapitant.Approved
RolofyllineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Rolofylline.Investigational
RomifidineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Romifidine.Vet Approved
RopiniroleDihydrocodeine may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Ropivacaine.Approved
RotigotineDihydrocodeine may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Dihydrocodeine.Approved
SafrazineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Safrazine.Withdrawn
SaquinavirThe metabolism of Dihydrocodeine can be decreased when combined with Saquinavir.Approved, Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Scopolamine.Approved
Scopolamine butylbromideThe risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Dihydrocodeine.Approved, Vet Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Dihydrocodeine.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Selegiline.Approved, Investigational, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Sepranolone.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Sertindole.Approved, Investigational, Withdrawn
SertralineThe metabolism of Dihydrocodeine can be decreased when combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Dihydrocodeine.Approved, Vet Approved
SildenafilThe metabolism of Dihydrocodeine can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Dihydrocodeine can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Dihydrocodeine can be increased when it is combined with Simeprevir.Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Dihydrocodeine.Approved
SolifenacinThe risk or severity of adverse effects can be increased when Solifenacin is combined with Dihydrocodeine.Approved
SpiradolineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Spiradoline.Investigational
SpironolactoneThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Spironolactone.Approved
St. John's WortThe serum concentration of Dihydrocodeine can be decreased when it is combined with St. John's Wort.Investigational, Nutraceutical
StiripentolThe serum concentration of Dihydrocodeine can be increased when it is combined with Stiripentol.Approved
SuccinylcholineSuccinylcholine may increase the bradycardic activities of Dihydrocodeine.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Dihydrocodeine.Approved, Investigational
SulfisoxazoleThe metabolism of Dihydrocodeine can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Sulpiride.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Sultopride.Experimental
SuvorexantDihydrocodeine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TandospironeThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Dihydrocodeine.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Tasimelteon.Approved
TelaprevirThe metabolism of Dihydrocodeine can be decreased when combined with Telaprevir.Approved, Withdrawn
TelithromycinThe metabolism of Dihydrocodeine can be decreased when combined with Telithromycin.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Dihydrocodeine.Approved
TerbinafineThe metabolism of Dihydrocodeine can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Tetracaine.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Tetrahydropalmatine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Tetrodotoxin.Investigational
ThalidomideDihydrocodeine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheobromineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Theobromine.Approved, Investigational
ThiamylalThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Thiamylal.Approved, Vet Approved
ThiazinamThiazinam may increase the hypotensive activities of Dihydrocodeine.Experimental
ThiethylperazineThiethylperazine may increase the hypotensive activities of Dihydrocodeine.Withdrawn
ThiopentalThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Thiopental.Approved, Vet Approved
ThioridazineThe metabolism of Dihydrocodeine can be decreased when combined with Thioridazine.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Thiothixene.Approved
TiagabineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Tiapride.Approved, Investigational
TiclopidineThe metabolism of Dihydrocodeine can be decreased when combined with Ticlopidine.Approved
TicrynafenThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Ticrynafen.Withdrawn
TiletamineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Tilidine.Experimental
TiotropiumThe risk or severity of adverse effects can be increased when Tiotropium is combined with Dihydrocodeine.Approved
TipranavirThe metabolism of Dihydrocodeine can be decreased when combined with Tipranavir.Approved, Investigational
TizanidineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Tizanidine.Approved
TocilizumabThe serum concentration of Dihydrocodeine can be decreased when it is combined with Tocilizumab.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Tolcapone.Approved, Withdrawn
ToloxatoneThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Toloxatone.Approved
TolterodineThe risk or severity of adverse effects can be increased when Tolterodine is combined with Dihydrocodeine.Approved, Investigational
TolvaptanThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Tolvaptan.Approved
TopiramateThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Topiramate.Approved
TorasemideThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Torasemide.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Dihydrocodeine.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe metabolism of Dihydrocodeine can be decreased when combined with Tranylcypromine.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Trazodone.Approved, Investigational
TriamtereneThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Triamterene.Approved
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Dihydrocodeine.Approved
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Tricaine methanesulfonate.Vet Approved
TrichlormethiazideThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Trichlormethiazide.Approved, Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Trichloroethylene.Experimental
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Dihydrocodeine.Approved
TrifluperidolThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Triflupromazine.Approved, Vet Approved
TrihexyphenidylThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Dihydrocodeine.Approved
TrimethaphanThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Dihydrocodeine.Approved, Investigational
TrimipramineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Triprolidine.Approved
TropatepineThe risk or severity of adverse effects can be increased when Tropatepine is combined with Dihydrocodeine.Experimental
TropicamideThe risk or severity of adverse effects can be increased when Tropicamide is combined with Dihydrocodeine.Approved
TrospiumThe risk or severity of adverse effects can be increased when Trospium is combined with Dihydrocodeine.Approved
TubocurarineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Dihydrocodeine.Approved
UlaritideThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Ularitide.Investigational
Valproic AcidThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Valproic Acid.Approved, Investigational
VecuroniumThe risk or severity of adverse effects can be increased when Vecuronium is combined with Dihydrocodeine.Approved
VenlafaxineThe metabolism of Dihydrocodeine can be decreased when combined with Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Veralipride.Experimental
VerapamilThe metabolism of Dihydrocodeine can be decreased when combined with Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Vigabatrin.Approved
Vinyl etherThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Vinyl ether.Experimental
VoriconazoleThe metabolism of Dihydrocodeine can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Vortioxetine.Approved
XenonThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Xenon.Experimental
XipamideThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Xipamide.Experimental
XylazineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Xylazine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Dihydrocodeine.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Ziconotide.Approved
ZimelidineDihydrocodeine may increase the serotonergic activities of Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Dihydrocodeine can be decreased when combined with Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Zolazepam.Vet Approved
ZolpidemDihydrocodeine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Dihydrocodeine.Approved
ZotepineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Zotepine.Approved, Investigational
ZuclopenthixolThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Zuclopenthixol.Approved, Investigational
Food Interactions
  • Alcohol may enhance CNS depressant effects

References

Synthesis Reference

Igor Likhotvorik, "Preparation of dihydrocodeine from codeine." U.S. Patent US06887999, issued May 03, 2005.

US06887999
General References
  1. Ammon S, Hofmann U, Griese EU, Gugeler N, Mikus G: Pharmacokinetics of dihydrocodeine and its active metabolite after single and multiple oral dosing. Br J Clin Pharmacol. 1999 Sep;48(3):317-22. [PubMed:10510141]
  2. Rowell FJ, Seymour RA, Rawlins MD: Pharmacokinetics of intravenous and oral dihydrocodeine and its acid metabolites. Eur J Clin Pharmacol. 1983;25(3):419-24. [PubMed:6628531]
  3. Schmidt H, Vormfelde SV, Walchner-Bonjean M, Klinder K, Freudenthaler S, Gleiter CH, Gundert-Remy U, Skopp G, Aderjan R, Fuhr U: The role of active metabolites in dihydrocodeine effects. Int J Clin Pharmacol Ther. 2003 Mar;41(3):95-106. [PubMed:12665158]
External Links
KEGG Drug
D01481
PubChem Compound
5284543
PubChem Substance
46506478
ChemSpider
4447600
ChEBI
135276
ChEMBL
CHEMBL1595
PharmGKB
PA449322
Drugs.com
Drugs.com Drug Page
Wikipedia
Dihydrocodeine
ATC Codes
N02AA58 — Dihydrocodeine, combinationsN02AA08 — Dihydrocodeine

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedTreatmentPain1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Dosage forms
FormRouteStrength
CapsuleOral
LiquidOral
TabletOral
SyrupOral
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)112.5 °CPhysProp
Predicted Properties
PropertyValueSource
Water Solubility2.38 mg/mLALOGPS
logP1.58ALOGPS
logP1.55ChemAxon
logS-2.1ALOGPS
pKa (Strongest Acidic)14.15ChemAxon
pKa (Strongest Basic)9.33ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area41.93 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity83.64 m3·mol-1ChemAxon
Polarizability32.82 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9942
Blood Brain Barrier+0.9974
Caco-2 permeable+0.8388
P-glycoprotein substrateSubstrate0.8754
P-glycoprotein inhibitor IInhibitor0.5937
P-glycoprotein inhibitor IINon-inhibitor0.9652
Renal organic cation transporterInhibitor0.5676
CYP450 2C9 substrateNon-substrate0.831
CYP450 2D6 substrateSubstrate0.9143
CYP450 3A4 substrateSubstrate0.7941
CYP450 1A2 substrateNon-inhibitor0.8554
CYP450 2C9 inhibitorNon-inhibitor0.9074
CYP450 2D6 inhibitorInhibitor0.7395
CYP450 2C19 inhibitorNon-inhibitor0.7689
CYP450 3A4 inhibitorNon-inhibitor0.8114
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.957
Ames testNon AMES toxic0.8074
CarcinogenicityNon-carcinogens0.9522
BiodegradationNot ready biodegradable0.9857
Rat acute toxicity2.9382 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9058
hERG inhibition (predictor II)Non-inhibitor0.8246
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0udi-0009000000-0621835c3e6c1a244d1c
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0udi-0009000000-215351ab6e3d6923cb7a
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0udi-0239000000-d9a28afb4f2a26a792fb
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0f6t-0931000000-8f6a91fec0761febddae
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-006t-0910000000-b17807fd1304c69ce71d
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0udi-0009000000-422aaa0732f083783954
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0udi-0009000000-6826eb02e5bf4f87fde7
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0udi-0359000000-b1a87ac83b5ead5b10ba
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0f6t-0941000000-85f127ae74a67d7544d7
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-006t-0910000000-fc3b87d3fb93d21f90f4
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-062d-0900000000-c8e88928923875169e0b

Taxonomy

Description
This compound belongs to the class of organic compounds known as morphinans. These are polycyclic compounds with a four-ring skeleton with three condensed six-member rings forming a partially hydrogenated phenanthrene moiety, one of which is aromatic while the two others are alicyclic.
Kingdom
Organic compounds
Super Class
Alkaloids and derivatives
Class
Morphinans
Sub Class
Not Available
Direct Parent
Morphinans
Alternative Parents
Phenanthrenes and derivatives / Tetralins / Coumarans / Anisoles / Aralkylamines / Alkyl aryl ethers / Piperidines / Trialkylamines / Secondary alcohols / Cyclic alcohols and derivatives
show 4 more
Substituents
Morphinan / Phenanthrene / Tetralin / Coumaran / Anisole / Alkyl aryl ether / Aralkylamine / Piperidine / Benzenoid / Cyclic alcohol
show 16 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Drug created on July 31, 2007 07:10 / Updated on November 09, 2017 03:01